ClinicaliQ Trial Snapshot
- Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine — Active Not Recruiting • Phase III • NCT03836040.
- Erenumab reduced monthly migraine days more than placebo in children and teenagers aged 6-17 with episodic migraines.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This study will evaluate the efficacy and safety of erenumab in migraine prevention in children (6 to